Understand the FDA Clock and Costs of Delay
Recognize the 180-day FDA response window and the escalating costs of delays, including engineering hours, missed launches, and potential for additional deficiency rounds.
This guide provides actionable tips for medical device manufacturers on how to effectively respond to FDA cybersecurity deficiency letters and additional information requests, aiming for a cleared submission and market launch without delays.
Major deficiencies typically allow 180 days to respond. Miss it and the submission is withdrawn.
Recognize the 180-day FDA response window and the escalating costs of delays, including engineering hours, missed launches, and potential for additional deficiency rounds.
Address deficiencies quickly to avoid extended FDA holds, which can lead to significant revenue impact and investor scrutiny.
Dissect the FDA hold letter line by line to accurately identify specific reviewer requests and the exact evidence needed for a complete response.
When the FDA requests additional information, provide precise and complete answers that directly address every question without oversharing unnecessary details.
Rebuild or strengthen flagged threat models to meet FDA expectations, ensuring alignment with AAMI TIR57 and industry best practices.
Conduct or redo penetration testing to address any gaps identified by the FDA, providing clear and reviewer-grade evidence of vulnerability management.
Identify and address missing documentation, such as incomplete SBOMs, SPDFs, or weak risk assessments, and build out the necessary artifacts.
Compile and format the entire deficiency response package, ensuring it is ready for eSTAR upload and easy consumption by the FDA reviewer.
Update risk assessments with clear traceability to ISO 14971 and ensure all cybersecurity documentation, including threat models, are connected to patient harm.
Authoritative guidance and standards underpinning this topic. Always confirm the latest revision with the publisher.
Quick answers to the questions teams most often ask about this topic.
It is the FDA's formal request for additional information when your premarket submission's cybersecurity package is incomplete or unclear. Receiving one pauses the review clock until you respond, so the quality and speed of your response directly affect time to clearance.
Address each deficiency individually with a clear, evidence-backed answer. Reference the exact section of your submission you are updating, attach the new artifact (updated threat model, SBOM, test report, etc.), and avoid introducing scope changes the reviewer didn't ask for.
Typically 180 days for a major deficiency, though this varies by submission type. Missing the deadline can result in your submission being placed on hold or withdrawn.